WO2000003703A1 - Medicaments contre les maladies allergiques - Google Patents

Medicaments contre les maladies allergiques Download PDF

Info

Publication number
WO2000003703A1
WO2000003703A1 PCT/JP1999/003851 JP9903851W WO0003703A1 WO 2000003703 A1 WO2000003703 A1 WO 2000003703A1 JP 9903851 W JP9903851 W JP 9903851W WO 0003703 A1 WO0003703 A1 WO 0003703A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
lymphocytes
drugs
blood cells
inflammation
Prior art date
Application number
PCT/JP1999/003851
Other languages
English (en)
French (fr)
Inventor
Katsuhiro Igeta
Kenji Tobetto
Ikuo Saiki
Shinjiro Odake
Tetsunori Fujisawa
Tetsu Matsuo
Tohru Oku
Original Assignee
Fuji Yakuhin Kogyo Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Kogyo Kabushiki Kaisha filed Critical Fuji Yakuhin Kogyo Kabushiki Kaisha
Priority to AU46531/99A priority Critical patent/AU4653199A/en
Priority to KR1020017000711A priority patent/KR20010083122A/ko
Priority to CA002337859A priority patent/CA2337859A1/en
Priority to EP99929875A priority patent/EP1101492A4/en
Publication of WO2000003703A1 publication Critical patent/WO2000003703A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP1999/003851 1998-07-17 1999-07-16 Medicaments contre les maladies allergiques WO2000003703A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU46531/99A AU4653199A (en) 1998-07-17 1999-07-16 Novel remedies for allergic diseases
KR1020017000711A KR20010083122A (ko) 1998-07-17 1999-07-16 신규한 알레르기 질환 치료제
CA002337859A CA2337859A1 (en) 1998-07-17 1999-07-16 Novel agents for treating allergic diseases
EP99929875A EP1101492A4 (en) 1998-07-17 1999-07-16 MEDICINE AGAINST ALLERGIC DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21866298 1998-07-17
JP10/218662 1998-07-17

Publications (1)

Publication Number Publication Date
WO2000003703A1 true WO2000003703A1 (fr) 2000-01-27

Family

ID=16723467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/003851 WO2000003703A1 (fr) 1998-07-17 1999-07-16 Medicaments contre les maladies allergiques

Country Status (6)

Country Link
EP (1) EP1101492A4 (ja)
KR (1) KR20010083122A (ja)
CN (1) CN1315858A (ja)
AU (1) AU4653199A (ja)
CA (1) CA2337859A1 (ja)
WO (1) WO2000003703A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006227A1 (fr) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la metalloprotease matricielle
WO2002055091A1 (en) * 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Antiallergic agents
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0703677D0 (en) * 2007-02-26 2007-04-04 Surface Therapeutics Ltd Novel compounds
WO2008156701A2 (en) * 2007-06-13 2008-12-24 The Brigham And Women's Hospital, Inc. Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN112999233B (zh) * 2019-12-19 2023-10-20 中国医学科学院药物研究所 一类来源于赤芍的单萜苷类化合物及其制法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002240A2 (en) * 1994-07-13 1996-02-01 Smithkline Beecham P.L.C. Use of inhibitors of human s-cd23

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD242802A1 (de) * 1983-02-28 1987-02-11 Univ Berlin Humboldt Verfahren zur herstellung neuer w(2'-naphthoxy)-hydroxamsaeuren enthaltende pharmazeutische zubereitungen und ihren salzen
US4654364A (en) * 1984-11-30 1987-03-31 E. R. Squibb & Sons, Inc. Hydroxamic acids of 7-oxabicycloheptane substituted ethers
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
JP2661841B2 (ja) * 1992-07-23 1997-10-08 ファイザー製薬株式会社 インドリン誘導体
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
AU6575094A (en) * 1993-04-27 1994-11-21 Wellcome Foundation Limited, The Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002240A2 (en) * 1994-07-13 1996-02-01 Smithkline Beecham P.L.C. Use of inhibitors of human s-cd23

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1101492A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
WO2002006227A1 (fr) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la metalloprotease matricielle
WO2002055091A1 (en) * 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Antiallergic agents

Also Published As

Publication number Publication date
CA2337859A1 (en) 2000-01-27
EP1101492A4 (en) 2002-09-25
AU4653199A (en) 2000-02-07
CN1315858A (zh) 2001-10-03
KR20010083122A (ko) 2001-08-31
EP1101492A1 (en) 2001-05-23

Similar Documents

Publication Publication Date Title
Harris et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
Andreani et al. Combination of coenzyme Q10 intake and moderate physical activity counteracts mitochondrial dysfunctions in a SAMP8 mouse model
Umar et al. Piperine ameliorates oxidative stress, inflammation and histological outcome in collagen induced arthritis
Sadique et al. Biochemical modes of action of Cassia occidentalis and Cardiospermum halicacabum in inflammation
Ismail et al. Anti-inflammatory activity of Salacia oblonga Wall. and Azima tetracantha Lam.
Powers Can antioxidants protect against disuse muscle atrophy?
Powers et al. Mechanisms of disuse muscle atrophy: role of oxidative stress
Chattopadhyay et al. Mechanism of antiulcer effect of Neem (Azadirachta indica) leaf extract: effect on H+-K+-ATPase, oxidative damage and apoptosis
Pinlaor et al. Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment
Rooban et al. Vitex negundo attenuates calpain activation and cataractogenesis in selenite models
Ray et al. Cell death in spinal cord injury (SCI) requires de novo protein synthesis: calpain inhibitor E‐64‐d provides neuroprotection in SCI lesion and penumbra
Kim et al. Inhibition of UVB‐Induced Skin Damage by Exopolymers from Aureobasidium pullulans SM‐2001 in Hairless Mice
Martín‐Romero et al. Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low‐potassium‐induced apoptosis of cerebellar granule cells
Tunçel et al. The protective effect of vasoactive intestinal peptide (VIP) on stress‐induced gastric ulceration in rats
WO2000003703A1 (fr) Medicaments contre les maladies allergiques
Lewandowski et al. Hidradenitis suppurativa: a review of current treatment options
Huang et al. The function of PPARγ/AMPK/SIRT-1 pathway in inflammatory response of human articular chondrocytes stimulated by advanced glycation end products
Hardeland Melatonin in healthy aging and longevity
Swamy et al. Influence of proton pump inhibitors on dexamethasone-induced gastric mucosal damage in rats
Lin et al. Chloride channel and inflammation-mediated pathogenesis of osteoarthritis
WO2000003734A1 (fr) Agents therapeutiques pour affections allergiques
Fu et al. [Retracted] Efficacy and Safety of Tripterygium Wilfordii Glycoside Tablets Combined with Acitretin Capsules in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
Aarabi et al. To estimate effective antiamyloidogenic property of melatonin and fisetin and their actions to destabilize amyloid fibrils
Ojo et al. Studies of the antioxidative effects of green and black tea (Camellia sinensis) extracts in rats
Lew et al. Peptidases that degrade gonadotropin‐releasing hormone: influence on LH secretion in the ewe

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810297.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09605665

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2337859

Country of ref document: CA

Ref document number: 2000 559838

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2337859

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999929875

Country of ref document: EP

Ref document number: PA/a/2001/000563

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017000711

Country of ref document: KR

Ref document number: 46531/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09743850

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999929875

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017000711

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999929875

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017000711

Country of ref document: KR